By Denny Jacob

Sanofi will terminate its proposed licensing agreement with Maze Therapeutics following opposition from the Federal Trade Commission.

The FTC on Monday said it would seek to block the healthcare company's proposed acquisition of an exclusive license to Maze's therapy in development for the treatment of Pompe disease. The regulator's complaint alleges the deal would protect Sanofi's monopoly and eliminate competition between Sanofi and Maze to develop new Pompe drugs.

Sanofi said it respectfully disagrees with the FTC's action and its partnership with Maze was designed to apply its resources to accelerate the development of MZE001.

"The delay associated with a long litigation has led Sanofi to conclude that it would not be in the best interests of patients to contest this litigation and Sanofi will therefore be terminating the agreement with Maze in accordance with its terms," Sanofi said.

The agreement between Sanofi and Maze for MZE001 was disclosed on May 1.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

December 11, 2023 17:03 ET (22:03 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Sanofi.
Sanofi (NASDAQ:SNY)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Sanofi.